Corrección en el artículo de Dalama et al. «Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica». (Revista Espanola de Cardiologia (2016) 69(11) (1088–1097)(S0300893216303785)(10.1016/j.recesp.2016.07.029));Correction to the Article by Dalama et al. “New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border”. (Revista Espanola de Cardiologia (2016) 69(11) (1088–1097)(S0300893216303785)(10.1016/j.recesp.2016.07.029));New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border;Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica

Revista Espanola de Cardiologia

Volumn 69, Issue 11, 2016, Pages 1088-1097

  Dalama, Belén ^a   Mesa, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cardiovascular disease; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ORAL ANTIDIABETIC AGENT; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CANAGLIFLOZIN; GLUCOSE BLOOD LEVEL; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM GLUCOSE COTRANSPORTER 2; URIC ACID;

BODY WEIGHT; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; ARTERIAL STIFFNESS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROTEINURIA; RISK; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PROTEINURIA; RISK; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; URIC ACID; VASCULAR STIFFNESS;

EID: 85016923678     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2016.11.044     Document Type: Erratum

References (73)

1. 1 Valdés, S., García-Torres, F., Maldonado-Araque, C., Goday, A., Calle-Pascual, A., Soriguer, F., et al. Prevalencia de obesidad, diabetes mellitus y otros factores de riesgo cardiovascular en Andalucía. Comparación con datos de prevalencia nacionales. Estudio Di@bet.es. Rev Esp Cardiol. 67 (2014), 442–448.
2. 2 Grupo de Trabajo de la SEC para la guía de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, revisores expertos para la guía de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, Comité de Guías de la SEC. Comentarios a la guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Society for the Study of Diabetes. Rev Esp Cardiol. 67 (2014), 87–93.
3. 3 Lee, T.M., Chou, T.F., Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 88 (2003), 531–537.
4. 4 Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab. 40 (2014), 176–185.
5. 5 Wright, E.M., Loo, D.D.F., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol Rev. 91 (2011), 733–794.
6. 6 Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 54 (2005), 3427–3434.
7. 7 Wilding, J.P.H., The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 63 (2014), 1228–1237.
8. 8 Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S.C., Boulton, D.W., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 53 (2014), 17–27.
9. 9 Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 124 (2014), 509–514.
10. 10 Del Prato, S., Nauck, M., Durán-Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 17 (2015), 581–590.
11. 11 Rosenstock, J., Vico, M., Wei, L., Salsali, A., List, J.F., Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1 c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 35 (2012), 1473–1478.
12. 12 Wilding, J.P.H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 16 (2014), 124–136.
13. 13 Jabbour, S.A., Hardy, E., Sugg, J., Parikh, S., Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 37 (2014), 740–750.
14. 14 Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 38 (2015), 376–383.
15. 15 Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W., List, J.F., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 33 (2010), 2217–2224.
16. 16 Bailey, C.J., Gross, J.L., Pieters, A., Bastien, A., List, J.F., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 375 (2010), 2223–2233.
17. 17 Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A., List, J.F., Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med., 11, 2013, 43.
18. 18 Nauck, M.A., Del Prato, S., Durán-García, S., Rohwedder, K., Langkilde, A.M., Sugg, J., et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 16 (2014), 1111–1120.
19. 19 Wilding, J.P.H., Norwood, P., T'joen, C., Bastien, A., List, J.F., Fiedorek, F.T., A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 32 (2009), 1656–1662.
20. 20 Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H.J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 1 (2013), 208–219.
21. 21 Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 37 (2014), 1650–1659.
22. 22 Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H.J., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 36 (2013), 3396–3404.
23. 23 Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 16 (2014), 147–158.
24. 24 Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U.C., Woerle, H.J., et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 17 (2015), 936–948.
25. 25 Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 37 (2014), 1815–1823.
26. 26 Ridderstråle, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2 (2014), 691–700.
27. 27 Stenlöf, K., Cefalu, W.T., Kim, K.-A., Alba, M., Usiskin, K., Tong, C., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 15 (2013), 372–382.
28. 28 Lavalle-González, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 56 (2013), 2582–2592.
29. 29 Wilding, J.P.H., Charpentier, G., Hollander, P., González-Gálvez, G., Mathieu, C., Vercruysse, F., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 67 (2013), 1267–1282.
30. 30 Schernthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 36 (2013), 2508–2515.
31. 31 Bode, B., Stenlöf, K., Sullivan, D., Fung, A., Usiskin, K., Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 41 (1995), 72–84 2013.
32. 32 Neal, B., Perkovic, V., De Zeeuw, D., Mahaffey, K.W., Fulcher, G., Ways, K., et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 38 (2015), 403–411.
33. 33 Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 124 (2014), 499–508.
34. 34 Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2 (2014), 369–384.
35. 35 Plosker, G.L., Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 74 (2014), 807–824.
36. 36 Yamout, H., Perkovic, V., Davies, M., Woo, V., De Zeeuw, D., Mayer, C., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 40 (2014), 64–74.
37. 37 Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85 (2014), 962–971.
38. 38 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol., 13, 2014, 28.
39. 39 Weir, M.R., Januszewicz, A., Gilbert, R.E., Vijapurkar, U., Kline, I., Fung, A., et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens. 16 (2014), 875–882.
40. 40 Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 38 (2015), 420–428.
41. 41 Ninomiya, T., Perkovic, V., Turnbull, F., Neal, B., Barzi, F., Cass, A., et al., Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ., 347, 2013, f5680.
42. 42 Zimlichman, R., Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep., 16, 2014, 479.
43. 43 Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 17 (2015), 1180–1193.
44. 44 Millán Longo, C., García Montero, M., Tebar Márquez, D., Beltrán Romero, L., Banegas, J.R., García Puig, J., Obesidad y episodios vasculares en la diabetes mellitus tipo 2. Rev Esp Cardiol. 68 (2015), 151–153.
45. 45 Wilson, P.W., Kannel, W.B., Silbershatz, H., D'Agostino, R.B., Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 159 (1999), 1104–1109.
46. 46 Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A.M., Sjöström, C.D., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 16 (2014), 159–169.
47. 47 Cefalu, W.T., Leiter, L.A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet Lond Engl. 382 (2013), 941–950.
48. 48 Neeland, I.J., McGuire, D.K., Chilton, R., Crowe, S., Lund, S.S., Woerle, H.J., et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 13 (2016), 119–126.
49. 49 ClinicalTrials.gov. Effects of dapagliflozin on epicardial fat in subjects with type 2 diabetes [citado 24 Abr 2016]. Disponible en: https://www.clinicaltrials.gov/ct2/show/NCT02235298.
50. 50 Škrtić, M., Cherney, D.Z.I., Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 24 (2015), 96–103.
51. 51 Panchapakesan, U., Pegg, K., Gross, S., Komala, M.G., Mudaliar, H., Forbes, J., et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?. PloS One., 8, 2013, e54442.
52. 52 Yale, J.-F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 15 (2013), 463–473.
53. 53 Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 38 (2015), 2344–2353.
54. 54 Monami, M., Nardini, C., Mannucci, E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 16 (2014), 457–466.
55. 55 Davies, M.J., Trujillo, A., Vijapurkar, U., Damaraju, C.V., Meininger, G., Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 17 (2015), 426–429.
56. 56 Rajasekeran, H., Lytvyn, Y., Cherney, D.Z.I., Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 89 (2016), 524–526.
57. 57 Scheen, A.J., SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf. 29 (2015), 1–26.
58. 58 Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 27 (2013), 479–484.
59. 59 Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 27 (2013), 473–478.
60. 60 Rosenstock, J., Seman, L.J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 15 (2013), 1154–1160.
61. 61 Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 38 (2015), 1687–1693.
62. 62 Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373 (2015), 2117–2128.
63. 63 ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events [citado 24 Abr 2016]. Disponible en: https://www.clinicaltrials.gov/ct2/show/NCT01730534.
64. 64 ClinicalTrials.gov. CANVAS-canagliflozin cardiovascular assessment study [citado 24 Abr 2016]. Disponible en: https://www.clinicaltrials.gov/ct2/show/NCT01032629.
65. 65 ClinicalTrials.gov. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy [citado 24 Abr 2016]. Disponible en: https://www.clinicaltrials.gov/ct2/show/NCT02065791.
66. 66 ClinicalTrials.gov. A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus [citado 24 Abr 2016]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01989754.
67. 67 Muskiet, M.H.A., Van Raalte, D.H., Van Bommel, E., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 3 (2015), 928–929.
68. 68 Ceriello, A., Genovese, S., Mannucci, E., Gronda, E., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 3 (2015), 929–930.
69. 69 Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., Von Eynatten, Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 375 (2016), 323–334.
70. 70 Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 39 (2016), 1108–1114.
71. 71 Dziuba, J., Alperin, P., Racketa, J., Iloeje, U., Goswami, D., Hardy, E., et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 16 (2014), 628–635.
72. 72 Sonesson, C., Johansson, P.A., Johnsson, E., Gause-Nilsson, I., Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol., 15, 2016, 37.
73. 73 Neal, B., Perkovic, V., De Zeeuw, D., Mahaffey, K.W., Fulcher, G., Stein, P., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J. 166 (2013), 217–223.